Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Binimetinib, Pemetrexed and Cisplatin, Followed by Maintenance With Binimetinib and Pemetrexed, in Patients With Advanced Non-small Cell Lung Cancer NSCLC With KRAS Mutations. A Multicenter Phase IB Trial.

NCT02964689 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02964689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02964689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Binimetinib, Pemetrexed and Cisplatin, Followed by Maintenance With Binimetinib and Pemetrexed, in Patients With Advanced Non-small Cell Lung Cancer NSCLC With KRAS Mutations. A Multicenter Phase IB Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
April 12, 2017
Completion date
July 2, 2021
Enrollment
18 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer, kras gene mutation, lung cancer